Dan Brennan

super strong quarter. You know, you highlighted the Omnis and some other things. I know you bumped the guide a bit, but it does imply a decel

Just wondering how we might think about the rest of your guidance in terms of what would drive here to the higher end to lower end

a little bit more color on how you're thinking about that going forward for the rest of the year?

do you feel like the guide fairly balances the puts and takes around the globe, or do you think there's some conservatism more so baked in?

Just any more color on the upgrade cycle as it progressing versus expectations. Is it ratable in '26?

Can you just unpack the three variables you kind of highlighted? Kinda how much are you spending? How much are you buying more inventory for yourself? How much was that a factor?

I think I heard NASD growing kind of north of 20%. So can you just unpack a little bit on what the outlook calls for for kind of in the back half of the year and as we look ahead?

what is your assumptions based upon for a market growth typically? Kinda what are you assuming? And kind of specifically, is it just pharma that's weaker?

In the Americas. I think you called that in the prepared remarks Americas Pharma XMASD was kind of maybe a weaker spot. You just unpack a little bit what's happening

can you just walk through the key levers to generate 5% growth next year, including what could push down or higher up

Where do you see the biggest opportunities? It's a question we get a lot from investors

would that imply a bit of a slowdown that you are starting the year at for consumables

Could you just unpack a little bit on the pharma piece? What you are seeing in life sciences

Life Science is probably, I guess, 0. Could you unpack a little bit

it's hard for us to parse what's really incremental, what's just shifting from one region to the other

Could you just speak to kind of know, what's baked in for the 2025 guide, how we think about that low double digits continuing

I think you talked about the seventh consecutive quarter of a book to bill that was solidly over one

the full year guide would imply a nice step-up in the back half of the year. So just can you walk through some of the visibility

any activity from the government in -- kind of reaction to the tariff wars

Can you just remind us, Rainer, of the linkage between orders and the forward growth for your Bioprocess business

how do we think about the impact of Danaher's kind of your overall growth from these patent expirations

Can you just unpack a little bit the strength there? You mentioned GEL strength in the quarter

what kind of protection do you have, certainty of closing, things like that

is it really just preclinical spending recovering that's gonna drive the strength in instruments and reagents? Are there any share potential there?

could you give any color underneath the thought about reagents and instruments. I know you said grew and were weak

Just kind of remind us how you're thinking about that business in the back half of the year

for US academic and government, you guys said 5% of revenues. What's kind of baked in now for the year from that front?

Just kind of wondering if you can unpack how you expect 2Q rest of year to play out for China

are you seeing pharma pause? Are you seeing any shift in there kind of spending

Just can you give us some of the puts and takes on how the quarter ended up and kind of what goes into that outlook?

are you seeing any signs of that? Just remind us how you think about what you're assuming for the rest of the year in U.S. academic and government?

Can you just speak to a little bit what you're seeing in that part of the business? Has it been a bit of a drag on your business?

is that just conservatism or maybe you were out punching the market in 2025

you want investors to like, 3% start at 3% for 2026 and around 1% the first quarter for organic. Is that right

Anyway, just help frame sizing magnitude or just any way to kind of contemplate what this can mean for Thermo Fisher

how much ultimately kind of the tariff changes occurred and kind of what's happening in 4Q

what type of maybe pharma R&D growth or other kind of factors you would kind of be using in order to support that 4% growth

So what's kind of assumed in the back half of the year there? Any color? I know you talked about book-to-bill ahead of one there

is there anything in the quarter itself -- I know there's a bunch of things that went right. Anything in the quarter itself that would lead you to believe it was temporary

what are you seeing from pharma now, like as they contemplate possible tariffs later in the year? Are they trying to accelerate orders now

beyond QA/QC part of the portfolio, excuse me, because you talked about mid-teens growth and the rest of the pharma a little bit slower

I think you said 4% for 2025? Just confirm that maybe feels a little conservative